Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cerapedics Receives Canadian Approval for Next-Gen Bone Graft - Orthopedic Design & Technology
OEM News

Cerapedics Receives Canadian Approval for Next-Gen Bone Graft

The first country to approve the commercial launch of i-FACTOR+ Matrix.

Cerapedics, a private ortho-biologics company, has announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix.
 
“We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+  Matrix,” said Glen Kashuba, chief executive officer of Cerapedics, “The matrix product leverages the clinically proven power of the P15 peptide combined with a collagen carrier for optimized interoperative delivery.”
 
“In addition to an anticipated commercial launch in Canada this October, the technology is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced. i-FACTOR+ Matrix is the same technology as the P15-L investigational material in the IDE.,” said Jeffrey Marx, Ph.D., president and chief operating officer of Cerapedics.
 
i-FACTOR Peptide Enhanced Bone Graft is based on proprietary small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation. In spinal fusion procedures, surgeons use a bone graft to join and stabilize vertebrae.
 
i-FACTOR Peptide Enhanced Bone Graft was approved in the European Union in 2008 and Australia in 2010 for use in the repair of bony voids or defects in orthopedic applications throughout the skeletal system (i.e., the spine and extremities). In the United States, i-FACTOR Peptide Enhanced Bone Graft was approved via a U.S. Food and Drug Administration (FDA) premarket approval (PMA) application in 2015 only for use in single-level anterior cervical fusion procedures. In 2018, the company enrolled the first patients in an IDE clinical trial, ASPIRE, evaluating the safety and efficacy of its next-generation product, P-15L Peptide Enhanced Bone Graft, for use in patients undergoing TLIF fusion surgery.

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters